Kornimate/medical-research-clean huggingface dataset:
high confusion: cannabis & driving

Conditions: Impairment, Cognitive; Impairment of Attention; Impairment, Psychomotor

Summary: this study is being done to assess the feasibility of administrating δ9-thc and δ8-thc isolates and simultaneously adopting several data harmonization measures to generate uniquely translatable data. this project aims to (1) evaluate the feasibility and acceptability of administering ∆9-thc and δ8-thc isolates using standardized cannabis dosing units to quantify ∆9-thc and δ8-thc pharmacokinetics; and (2) evaluate the feasibility and acceptability of adopting standardized impairment detection methods and driving performance definitions and measures on quantifying ∆9-thc and δ8-thc driving impairment compared to a placebo.


Eligibility criteria:
inclusion criteria: * at least 18 years of age, no older than 49 years of age * recent cannabis use (within past two years) * good mental health as determined by self-reported responses to the psychopathology screener * absence of any major medical, cardiovascular, endocrine, and neurological condition as determined by self-reported responses to the medical history screener * in possession of a valid drivers' license with at least two years of driving experience * english-speaking (able to provide consent and complete questionnaires) * written informed consent exclusion criteria: * any serious prior adverse response to cannabis * history of or current substance use disorder as determined by self-reported responses to the internalizing, externalizing, and substance use disorder screener * pregnancy or lactation (pregnancy test, if needed) * use of medications that may impact driving ability (e.g., mood stabilizers, sedatives)

Keywords: cannabis impairment tetrahydrocannabinol
evaluation of exercise benefits to promote health aging among chronically ill geriatrics in a community

Conditions: Diabetes; Hypertension; Osteoporosis; Osteoarthritis

Summary: the aim of this study is to evaluate the effect of hydraulic resistance circuit training for elderly people with chronic illness.

this study is divided into three years. the aim of the first year is to analyze the types and percentage of chronic illness in middle- and old-aged population in communities and the impact on their physical and mental function. the second year, we will use proper exercise prescriptions with exercise equipment available for chronic illness population and examine the improvement of their physical and mental functions after exercise intervention. the third year, we will adopt the concept of social marketing to promote knowledge about health-related fitness and exercise to communities and help to establish exercise center. to chronic illness people, the study seeks to delay the progression of disease and disability by encouraging them to participate in prescribed exercises. to relatively healthy people, exercise can achieve the purposes of healthy aging, decreased chronic illness, and improved adls function and life quality.

Eligibility criteria:
inclusion criteria: subjects were recruited at the age of 45-80, and can communicate verbally and in writing. exclusion criteria: subjects had physical limitation in sports and were advised not to exercise by doctors.

Keywords: aging chronic illness resistance circuit training
exercise training in healthy young men

Conditions: Gaining Skeletal Muscle Mass and Strength

Summary: resistance type exercise training has been shown to be a potent stimulus to increase skeletal muscle mass and strength in healthy men. furthermore, timed protein intake is also known to affect the muscle adaptive response following exercise. whether timed protein intake could augment the increase in muscle fiber size and/or satellite cell content following long-term exercise intervention remains to be established. we hypothesize that protein supplementation before sleep, on both training and non-training days, during a 12 week resistance training program further increases type ii muscle fibre cross sectional area when compared to the placebo group.


Eligibility criteria:
inclusion criteria: * male * healthy * age between 18 and 30 years * bmi between 18.5 and 30 kg/m2 * recreationally active, performing sports on a non-competitive basis between 2 and 5 hours p/wk * participants willing and able to give written informed consent and to understand, to participate and to comply with the biomedical research project requirements exclusion criteria: * hba1c level above 6.5% * fasted blood glucose level above 7 mmol/l * serum creatinine level beneath 60 or above 120 µmol/l * participants with a recent history or current state of copd * participants with a recent history or current state of rheumatoid arthritis * participants with a recent history or current state of musculoskeletal/orthopedic disorders * participants with a recent history or current state of renal disorder * participants with a recent history or current state of cognitive impairment * participants with orthopedic metal implants in the spine and/or upper/lower extremities * participants with lactose intolerance and/or dairy protein allergy * participants who are enrolled in an interventional biomedical research project or have received an investigational new drug or product with the last 30 days prior to screening. * participants on medication, including anticoagulants

Keywords: muscle mass strength cross-sectional area protein
the validation of rockall scoring system in predicting outcomes from variceal bleeding

Conditions: Bleeding Esophageal

Summary: objective this study aims to evaluate the validation of the rockall scoring system in predicting the outcomes of variceal bleeding among sudanese patients. design/method a cross-sectional hospital-based study involved 150 adult sudanese patients presenting with upper gastrointestinal bleeding (ugib) of variceal origin. patients with ugib resulting from causes other than varices and those who declined participation were excluded. data were collected through a structured questionnaire complemented by upper gastrointestinal tract endoscopy findings, and patients were followed up until discharge. results the study encompassed 150 patients, predominantly male (117, 78%), aged between 18 and 60 years (n=119, 79%), residing mainly in central regions (134, 89%). the leading presenting complaints included hematemesis (70, 46.7%) and melena (22, 14.6%). notably, peri-portal fibrosis (101, 67.3%) and cirrhosis (24, 16%) were the primary etiological factors, with a significant prevalence of alcohol consumption (87, 58%). concerning the grade of esophageal varices, grades iii and iv were most prevalent (67, 44.7% and 47, 31.3%, respectively), and fundal varices were identified in 13 patients (8.7%). the mean rockall score was 3.83 ± 1.99, indicating moderate severity. additionally, the rockall score showed significant associations with the number of sessions, complications, bleeding recurrence, duration of hospital stay, and mortality (p \< 0.05). conclusion understanding the significance of the rockall scoring system and its applicability to sudanese patients with variceal bleeding has the potential to guide more effective strategies in the management of upper gastrointestinal tract bleeding, ultimately improving patient outcomes and reducing morbidity and mortality.


Eligibility criteria:
inclusion criteria: * aged 18 years and older * primary complaints of upper gi bleeding exclusion criteria: * patients with upper gi bleeding resulting from causes other than varices * who declined to participate in the study
high sensitive troponin t (hstnt) and copeptin as prognostic parameters in patients with elective total endoprosthesis

Conditions: Perioperative Myocardial Infarctions; Pulmonary Embolism

Summary: summary: the purpose of the study is to prove if the biomarker high sensitive troponin t (hstnt) and the biomarker of endogenous stress copeptin can serve as surrogate parameter of prognosis in patients with elective knee and hip total endoprosthesis.

consecutively, high sensitive troponin t and copeptin will be measured in all patients with elective knee and hip endoprosthesis in the orthopedic department of the university of heidelberg. the blood is taken during the routine blood testes if possible, on admission and the days 1-4 following the operation. usual baseline characteristics are taken as well as usual blood results (hb, cholesterol and so on). primary endpoint is the detection of perioperative myocardial infarction and pulmonary embolism.

Eligibility criteria:
inclusion criteria: * consecutive patients with elective knee and hip endoprosthesis exclusion criteria: * not willing or not able to take part in the observational trial * no written inform consent
a study of patients who recently have been infected with hiv

Conditions: HIV Infections

Summary: the purpose of this study is to find out if anti-hiv drugs, taken by patients who are newly infected with hiv, can make the level of hiv in the body too low to detect. studying patients who recently have been infected with hiv may help researchers understand how hiv infection works and how anti-hiv drugs may help these patients. approved anti-hiv drugs can reduce the amount of hiv, but more research needs to be done in newly infected patients. this study will look at recently hiv-infected patients to study the progression of hiv disease and to see whether anti-hiv drugs can reduce the level of hiv.

primary and early hiv infection represents a potentially unique opportunity to better understand the pathogenesis of hiv infection, as well as to potentially prevent the establishment of latent infection. approved antiretroviral therapy is able to reduce plasma viremia to unmeasurable levels in established infection and several groups have observed comparable effects in recently infected adults. this study is designed to evaluate and follow a cohort of patients with primary or early hiv infection and to evaluate the time course of latent infection and whether latent infection in cd4 cells will allow viral persistence despite antiretroviral therapy. patients begin antiretroviral therapy within 7 days of enrollment. all patients are evaluated for treatment compliance and complete a compliance questionnaire regularly. clinical evaluations, including cd4, cd8, and hiv rna counts also are done regularly. antiretroviral therapy is discontinued if there is no detectable virus by ultrasensitive assay and culture techniques in plasma, pbmcs, and lymphoid tissue. in a subset of patients, genital secretions and csf (cerebrospinal fluid) are evaluated. if relapse occurs, antiretroviral therapy is re-instituted. in addition, virology and immunology substudies are performed.

Eligibility criteria:
inclusion criteria patients may be eligible for this study if they: * have had certain tests indicating that they recently have been infected with hiv. * agree to use effective methods of birth control during the study and for 3 months after. * are at least 18 years old. exclusion criteria patients will not be eligible for this study if they: * have taken anti-hiv drugs. * take erythropoietin, g-csf or gm-csf within 30 days of study entry. * take interferons, interleukins, cytotoxic chemotherapy, or hiv vaccines within 30 days of study entry. * take medications that should not be taken with their prescribed anti-hiv drugs. * have had radiation treatment within 30 days of study entry. * are pregnant or breast-feeding.

Keywords: virus replication hiv-1 polymerase chain reaction dna, viral rna, viral sensitivity and specificity anti-hiv agents viral load proviruses acute infection
nicotine gum recovery after colorectal surgery

Conditions: Post-operative Ileus

Summary: the purpose of this study is to evaluate whether the use of nicotine gum in the postoperative period influences surgical outcome in patients undergoing colorectal surgery.

the main hypothesis of this study is that use of nicotine gum after colorectal surgery will accelerate recovery of bowel function. eligible patients include all patients undergoing segmental small bowel or large bowel resection with a planned primary anastomosis, planned removal of the nasogastric tube at the end of the surgery, and administration of clear liquids on post-operative day one. patients who have an ileostomy or colostomy created will be excluded. patients enrolled in the study will be randomized to one of three groups: nicotine gum, regular gum, or no gum. patients randomized to nicotine gum or regular gum will chew the gum three times a day for 1 week. the main outcome measure is time to first bowel movement or flatus.

Eligibility criteria:
inclusion criteria: * able to freely give written informed consent to participate in the study and have signed the informed consent form; * due to undergo small and/or large partial bowel resection via laparotomy or laparoscopy; exclusion criteria: * prior intestinal surgery * mentally incompetent or unable or unwilling to provide informed consent or comply with study procedures * american society of anesthesiologists (asa) class iv or v; * history of abdominal carcinomatosis; * history of radiation enteritis; * children \ 85 years of age * pregnant women * current cigarette, cigar smokers and chewers of tobacco. ex smokers who quit less than 3 months ago. * patients requiring postoperative ventilation, pressor requirement or icu stay * patients with prior cardiovascular disorders

Keywords: ileus
jing si herbal tea in the treatment of dyspeptic symptoms

Conditions: Functional Gastrointestinal Disorders; Healthy Subjects

Summary: dyspepsia refers to chronic or recurrent upper gastrointestinal symptoms. according to the rome iv criteria, functional dyspepsia (fd) symptoms included meal-related fullness, early satiation, epigastric pain or burning which are unexplained after routine investigation. fd causes substantial psychophysical burden because of its unknown etiology and high prevalence. although fd is currently associated with local inflammation of the gastrointestinal tract and microbiota alteration, current available treatments for fd are of limited effectiveness. in view of this, many studies have applied chinese herbal medicine in fd and achieved some therapeutic benefit. the jing si herbal tea composed of eight native taiwanese herbs (wormwood, hickory grass, ophiopogon japonicus, houttuynia cordata, platycodon, licorice, perilla leaves, chrysanthemum) has obtained a special export license from the ministry of health and welfare. the jing si herbal tea also has been registered in clinical trials as a complementary treatment for covid-19. the preliminary data demonstrated that the jing si herbal tea may improve gastrointestinal symptoms and anxiety in patients with covid-19. therefore, this study aims to investigate the impact of the jing si herbal tea on psychophysical burden and metabolites of microbiota in patients with fd through a double-blind randomized manner.


Eligibility criteria:
inclusion criteria: 1. age between 20-79 years old. 2. those who meet the definition of functional dyspepsia (fd). (functional dyspepsia (fd) is chronic (once a week, lasting at least three months, at least six months before the first symptom) upper gastrointestinal symptoms (any of the following): postprandial abdominal distension, easy to feel full, epigastric pain or burning sensation in the upper abdomen, and no symptoms of gastrointestinal bleeding or significant weight loss, no abnormality after upper gastrointestinal endoscopy). 3. be conscious and willing to sign the subject's consent form. exclusion criteria: 1. abnormal liver and kidney function; 2. abnormal blood tests and thyroid abnormalities; 3. have received surgery on the digestive tract; 4. abnormal upper gastrointestinal endoscopy; 5. have gastric pylori infection; 6. antibiotics are being used for infectious diseases; 7. pregnant or breastfeeding women; 8. suffering from heart, liver, or kidney failure; 9. physical weakness, allergies, coldness, chronic diseases, poor kidney function, infants under three years old, children, pregnancy, lactation, menstrual period.

Keywords: jing si herbal tea liquid packet psychophysical burden
study evaluating darbepoetin alfa in subjects with chronic kidney disease (ckd) receiving dialysis

Conditions: Kidney Disease; Chronic Kidney Disease

Summary: the proposed study is designed to test a novel dosing paradigm that would facilitate the treatment of anemia in ckd patients on dialysis. anemic patients on hemo and peritoneal dialysis who have achieved and maintained target hemoglobin (hb) on every other week (q2w) dosing of darbepoetin alfa will have the dosing interval extended to once monthly (qm) dosing.


Eligibility criteria:
inclusion criteria: * diagnosis of chronic kidney disease (ckd) and receiving dialysis for \> 3 months before enrollment * clinically stable, in the judgment of the investigator * mean hb \> 11.0 g/dl (110 g/l) to \< 13.0 g/dl (130 g/l) * transferrin saturation (tsat) \> 19.5% * serum vitamin b12 and folate levels above the lower limit of the normal range * receiving stable q2w iv or sc doses of aranesp® (darbepoetin alfa). a stable dose is defined as less than or equal to 25% change in dose over the 6-week period immediately prior to enrollment and with no missed doses in this period exclusion criteria: * scheduled to receive a kidney transplant * diastolic blood pressure greater than 110 mm hg or systolic bp greater than 180 mm hg during screening * acute myocardial ischemia * hospitalization for congestive heart failure, myocardial infarction, deep vein thrombosis, stroke or transient ischemic attack within 12 weeks before enrollment * parathyroid hormone (pth) level greater than 1500 pg/ml (158.0 pmol/l) * major surgery within 12 weeks before enrollment (excluding vascular access surgery) * currently receiving antibiotic therapy for systemic infection * known positive hiv antibody or positive hepatitis b surface antigen * clinical evidence of current malignancy and/or receiving systemic chemotherapy/radiotherapy with the exception of basal cell or squamous cell carcinoma of the skin and cervical intraepithelial neoplasia * red blood cell (rbc) transfusions within 8 weeks before enrollment * androgen therapy within 8 weeks before enrollment - systemic hematologic disease (e.g., sickle cell anemia, myelodysplastic syndromes, hematologic malignancy, myeloma, hemolytic anemia) * any disorder that may impact (in the judgment of the investigator) the ability to give informed consent for participation in this study * pregnant or breast-feeding women * all subjects must practice adequate contraception (in the judgment of the investigator) throughout this trial * treatment with an investigational agent or device within 30 days before enrollment or scheduled to receive an investigational agent other than those specified by this protocol during the course of this study

Keywords: chronic kidney disease, ckd renal failure anemia hemodialysis peritoneal dialysis aranesp®, darbepoetin alfa
evaluation of the diagnostic role of hysterosalpingography in cesarean scar niche diagnosed by hysteroscopy

Conditions: Cesarean Section Complications

Summary: the term cs niche (defect) describes the presence of a hypoechoic area within the myometrium in the isthmus (lower uterine segment) with discontinuation of myometrium at the site of previous cs. hysterosalpingography is an important component in the diagnostic evaluation of the infertile woman. the number of hysterosalpingography examinations performed has significantly increased in recent years, likely due to the trend for women delaying pregnancy until later in life and the popularity of technical advances achieved in reproductive medicine.the term cs niche (defect) describes the presence of a hypoechoic area within the myometrium in the isthmus (lower uterine segment) with discontinuation of myometrium at the site of previous cs. the main purpose of the study is to evaluate the diagnostic role of hsg to early detect cesarean scar niche. to evaluate diagnostic role of hysterosalpingography (hsg) in cesarean scar niche at early cancer detection and gynecological endoscopy unit at ain shams maternity hospital within 6 months.


Eligibility criteria:
inclusion criteria * age more than 18 years. * previous history of cesarean delivery. * cesarean scar niche confirmed by hysteroscopy. * premenopausal status exclusion criteria: * pregnancy. * contrast allergy. * active pelvic infection. * medical history interfering with hsg.
balloon eustachian tuboplasty in treatment of chronic eustachian tube dysfunction

Conditions: Chronic Eustachian Tube Dysfunction; Chronic Recurrent Otitis Media; Effusion After Tympanostomy

Summary: the prevalence of eustachian tube (et) dysfunction in adults reaches 1%. it causes a feeling of fullness in the ear, otalgia and hearing loss and can lead to recurrent acute otitis media, development of chronic otitis media with effusion and cholesteatoma. endoscopic transnasal balloon et dilatation is a novel surgical technique for et dysfunction. the main goal is to restore et function by dilation its cartilaginous part leading to better ventilation and drainage of the middle ear. however, its real effect in the treatment of particular subgroups of patients with et dysfunction remains unknown. patients are mostly evaluated as one group. adults with chronic et dysfunction will be strictly divided into particular subgroups and included in the study. subgroups will be compared in order to identify treatment effect in particular subgroups.

the prevalence of eustachian tube (et) dysfunction in adults reaches 1%. it causes a feeling of fullness in the ear, otalgia and hearing loss and can lead to recurrent acute otitis media, development of chronic otitis media with effusion and cholesteatoma. endoscopic transnasal balloon et dilatation is a novel surgical technique for et dysfunction. the main goal is to restore et function by dilation its cartilaginous part leading to better ventilation and drainage of the middle ear. however, its real effect in the treatment of particular subgroups of patients with et dysfunction remains unknown. patients are mostly evaluated as one group. adults with chronic et dysfunction will be strictly divided into particular subgroups and included in the study. the otomicro(endo)scopy, symptoms severity according to vas (visual analogue pain scale), etdq-7 (eustachian tube dysfunction questionnaire) questionnaire, tympanometry, audiometry and the possibility of valsalva and toynbee maneuver will be used to evaluate the effect of balloon et dilatation. only patients with standard treatment failure will be included in the study. tuboplasty with and without myringotomy will be performed (and compared) in patients with chronic otitis media with effusion. subgroups will be compared in order to find patients who could profit from the treatments the most.

Eligibility criteria:
inclusion criteria: * adult patients with chronic eustachian tube dysfunction lasting more than 6 months, with or without recurrence of chronic otitis media with effusion after tympanostomy exclusion criteria: * anatomic obstruction in nasopharynx * nasopharyngeal cancer * head and neck cancer * other middle ear surgery except for myringotomy or tympanostomy * chronic suppurative otitis media * patients who could not undergo general anesthesia * patients who did not give consent to be included in the study

Keywords: otitis media with effusion balloon tuboplasty eustachian tube eustachian tube dysfunction